Pasithea TherapeuticsKTTA
13F holders, Q4 2024 (December 31)7holders +1
1new positions
0sold out
$3.15avg. 13F price*
At the end of Q4 2024, 7 institutions reported holding Pasithea Therapeutics Corp. (KTTA) in their 13F filings, up 1 from Q3 2024. 1 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($192K), UBS Group AG ($41K) and Tower Research Capital LLC (TRC) ($6K).
- Company
- Pasithea Therapeutics Corp.
- CUSIP
- 70261F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $192K |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 68,586 shares bought and 510 shares sold, net +68,076 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Armistice Capital, LLC | 0.00% | New | 61,000 | $192K |
| UBS Group AG | 0.00% | Add +96.0% | 12,868 | $41K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +213.8% | 1,886 | $6K |
| Morgan Stanley | 0.00% | Reduce -33.3% | 1,000 | $3K |
| Royal Bank of Canada | 0.00% | No change | 250 | $1K |
| JPMorgan Chase & Co. | 0.00% | No change | 150 | $473 |
| Bank of America Corp. | 0.00% | Reduce -55.6% | 8 | $25 |
"% of holder's portfolio" is KTTA's weight in each manager's 13F, not the share of Pasithea Therapeutics Corp. the manager owns.